

Living with

Hypertension

is a tough option...



your easy option... a quality ACE inhibitor

CARDACE

5mg & 10mg
Tablets

[Enalapril Maleate]

CARDACE-H

Tablets

[Enalapril Maleate + Hydrochlorothiazide]

A Time Tested Option in Hypertension

ACE inhibitor with Diuretic

Like...


- ⊕ Essential Hypertension
- ⊕ Renovascular Hypertension
- ⊕ Regression of Ventricular Hypertrophy
- ⊕ Heart Failure
- ⊕ Diabetic Nephropathy

Your trusted option because....

- ⊕ Gold standard in uncontrolled hypertension
- ⊕ Cost effective
- ⊕ Twice the decline in side effects
- ⊕ Twice the efficacy
- ⊕ Two salts at the price of one

Definite choice in

Essential hypertension
Uncontrolled hypertension
In mild to moderate renal failure



BRIEF PRESCRIBING INFORMATION:

Cardace (Enalapril Maleate USP) is the maleate salt of Enalapril, a derivative of two amino-acids, L-alanine and L-proline. Following oral tablet administration, Enalapril is rapidly absorbed and hydrolysed to Enalaprilate, which is a highly specific long acting, non-sulphydryl angiotensin converting enzyme inhibitor. **INDICATIONS:** All grades of essential hypertension, Renovascular hypertension, All degrees of heart failure, prevention of symptomatic heart failure, prevention of coronary ischaemic events. **DOSAGE AND ADMINISTRATION:** Since absorption of tablets Cardace is not affected by food, the tablet may be administered before, during or after meals. **Essential Hypertension:** The initial dose is 10 to 20mg. The dosage should be adjusted according to the need of patients, to a maximum of 40mg daily. **Concomitant diuretic therapy in hypertension:** The diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with cardace. If this is not possible, then initial dose of cardace should be low (5mg or less) to determine the initial effect on blood pressure, dosage should then be adjusted according to the need of patients. **Renovascular Hypertension:** Since blood pressure and renal function in such patients may be particularly sensitive to ACE inhibition, therapy should be initiated with a lower starting dose e.g. 5mg or less. **Dosage in Renal insufficiency:** Generally, the intervals between the administration of Enalapril should be prolonged and/or the dosage reduced. **Mild impairment—60-30ml/min creatinine clearances 5-10mg initial dose Moderate impairment—30-10ml/min creatinine clearance 2.5-5mg initial dose, Severe impairment (dialysis patients) 1.5-10ml/min creatinine clearance 2.5mg and in heart failure or asymptomatic left ventricular dysfunction is 2.5mg and it should be administered under close medical supervision to determine the initial effect on the blood pressure. **CONTRAINDICATIONS:** Enalapril maleate is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedematous edema relating to previous treatment with an ACE inhibitor and in patient with hereditary or idiopathic angioedema. **SIDE EFFECTS:** The following side effects have been associated with the use of Enalapril maleate: Dizziness, Headache, Fatigue, Asthenia, Hypotension, Orthostatic Hypotension, Syncope, Nausea, Diarrhea, Muscle Cramps, Rash, Cough and Renal Dysfunction. **PRESENTATION:** Cardace tablets 5mg and 10mg are supplied in blister packs of 20's (2x10's strips).**

BRIEF PRESCRIBING INFORMATION:

Cardace-H (Enalapril Maleate 5mg and Hydrochlorothiazide 12.5mg) is a combination of an Angiotensin Converting Enzyme inhibitor (Enalapril Maleate) and a Diuretic (Hydrochlorothiazide). **INDICATION:** The use of Cardace-H is recommended in hypertensive patient for whom the combination therapy is appropriate. **DOSAGE AND ADMINISTRATION:** In Hypertension: Usually one or two tablets, given once daily. Dosage should be adjusted according to blood pressure. **Prior Diuretic Therapy:** Diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with Cardace-H. **Dosage in Renal Insufficiency:** Thiazols may not be appropriate diuretics for use in patients with renal impairment and are ineffective at Creatinine clearance values of 50ml/min or below (i.e. moderate or severe renal insufficiency). In patient with Creatinine clearance of >30 and <80ml/min Cardace-H should be used only after titration of the individual components. The recommended initial dose of Enalapril Maleate, when used alone, in mild renal insufficiency is 5-10 mg. **CONTRAINDICATION:** Anuria. Cardace-H is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedematous edema relating to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. **PRECAUTION:** Symptomatic hypotension may occur in some patients. In known patients with ischemic heart or cerebrovascular disease, special consideration should be given when therapy is administered because an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident. ACE's should be given with caution to patients with obstruction in the outflow tract of the left ventricular tract. It should be given with great caution in patients with hepatic disease, since minor alteration of fluid and electrolyte balance can cause hepatic coma. **PREGNANCY AND LACTATION:** As ACE's can cause fetal and neonatal morbidity and mortality when administered to a pregnant women during the 2nd and 3rd trimesters, so the use of Cardace-H during pregnancy is not recommended, unless it is considered life saving for the mother. As the drug appears in human milk, if the use of drug is necessary the patient should stop nursing. **SIDE EFFECTS:** Cardace-H is usually well tolerated. In clinical studies, side effects have usually been mild and transient, and usually do not require discontinuation of therapy. **PRESENTATION:** Cardace-H is supplied in blister pack of 20's (2x10's strips).

“Medicines For All”



Zafa Pharmaceutical Laboratories (Private) Limited

L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN)

Email: zafaph@cyber.net.pk Website: www.zafa.com.pk



ISO 9001:2000